Therapeuticsmd Inc (TXMD)

2026-05-12T21:18:55.000Z - 7 weeks ago

TherapeuticsMD reports Q1 EPS 1c vs. (6c) last year

May 12, 2026, 4:05 PM EDT - 7 weeks ago

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026, 4:00 PM EDT - 7 weeks ago

TherapeuticsMD Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 7 weeks ago

TherapeuticsMD Quarterly report: Q1 2026

2026-03-30T20:23:59.000Z - 3 months ago

TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year

Mar 30, 2026, 4:05 PM EDT - 3 months ago

TherapeuticsMD Announces Full Year 2025 Financial Results

Mar 30, 2026, 7:00 AM EDT - 3 months ago

TherapeuticsMD Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

TherapeuticsMD Annual report: Q4 2025

2025-11-12T21:15:33.000Z - 8 months ago

TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year

Nov 12, 2025, 4:05 PM EST - 8 months ago

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Nov 6, 2025, 6:00 AM EST - 8 months ago

TherapeuticsMD Earnings release: Q3 2025

Nov 6, 2025, 6:00 AM EST - 8 months ago

TherapeuticsMD Quarterly report: Q3 2025

Nov 3, 2025, 7:00 AM EST - 8 months ago

TherapeuticsMD Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 8 months ago

TherapeuticsMD Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 9 months ago

TherapeuticsMD Proxy statement: Proxy Filing

2025-08-12T20:40:35.000Z - 11 months ago

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

Aug 12, 2025, 4:05 PM EDT - 11 months ago

TherapeuticsMD Announces Second Quarter 2025 Financial Results

Aug 12, 2025, 12:00 AM EDT - 11 months ago

TherapeuticsMD Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 11 months ago

TherapeuticsMD Earnings release: Q2 2025

2025-05-13T20:15:52.000Z - 1 year ago

TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year

May 13, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Earnings release: Q1 2025

Mar 27, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces Full Year 2024 Financial Results

Mar 27, 2025, 2:00 AM EDT - 1 year ago

TherapeuticsMD Annual report: Q4 2024

Mar 27, 2025, 2:00 AM EDT - 1 year ago

TherapeuticsMD Earnings release: Q4 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

TherapeuticsMD Announces Third Quarter 2024 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

TherapeuticsMD Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

TherapeuticsMD Quarterly report: Q3 2024

Oct 25, 2024, 8:00 AM EDT - 1 year ago

TherapeuticsMD Proxy statement: Proxy Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

TherapeuticsMD Proxy statement: Proxy Filing

Aug 23, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Quarterly report: Q2 2024

Aug 23, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Earnings release: Q2 2024

Aug 12, 2024, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces Second Quarter 2024 Financial Results

2024-05-10T20:06:17.000Z - 2 years ago

TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year

May 10, 2024, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces First Quarter 2024 Financial Results

May 10, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Quarterly report: Q1 2024

May 10, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Earnings release: Q1 2024

Mar 29, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Announces Full Year 2023 Financial Results

Mar 29, 2024, 8:00 AM EDT - 2 years ago

TherapeuticsMD Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

TherapeuticsMD Annual report: Q4 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

TherapeuticsMD Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:00 PM EST - 2 years ago

TherapeuticsMD Quarterly report: Q3 2023

Nov 14, 2023, 4:00 PM EST - 2 years ago

TherapeuticsMD Earnings release: Q3 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q2 2023

2023-08-14T10:51:58.000Z - 3 years ago

TherapeuticsMD reports Q2 EPS (24c) vs. ($1.70) last year

Aug 14, 2023, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Second Quarter 2023 Financial Results

May 17, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

May 17, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

May 15, 2023, 4:05 PM EDT - 3 years ago

TherapeuticsMD Announces First Quarter 2023 Financial Results

May 15, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q1 2023

May 1, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

Apr 7, 2023, 4:01 PM EDT - 3 years ago

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Apr 7, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Annual report: Q4 2022

Apr 7, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q4 2022

2023-01-11T12:20:19.000Z - 3 years ago

TherapeuticsMD reinstated with a Neutral at Cantor Fitzgerald

Jan 3, 2023, 6:50 AM EST - 3 years ago

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

2022-12-05T07:39:07.000Z - 3 years ago

TherapeuticsMD Inks Licensing Deal with Mayne Pharma

2022-12-04T23:04:12.000Z - 3 years ago

TherapeuticsMD enters agreements to license products to Mayne Pharma

Dec 4, 2022, 6:00 PM EST - 3 years ago

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

2022-11-14T21:10:01.000Z - 3 years ago

TherapeuticsMD reports Q3 EPS ($3.13) vs. ($5.62) a year ago

Nov 14, 2022, 4:05 PM EST - 3 years ago

TherapeuticsMD Announces Third Quarter 2022 Financial Results

Nov 14, 2022, 9:00 AM EST - 3 years ago

TherapeuticsMD Quarterly report: Q3 2022

Nov 14, 2022, 9:00 AM EST - 3 years ago

TherapeuticsMD Slides: Q3 2022

Oct 31, 2022, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Additional $7 Million Private Placement

Oct 3, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces $7 Million Private Placement

Sep 12, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q2 2022

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Quarterly report: Q2 2022

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Slides: Q2 2022

Aug 15, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Aug 8, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

2022-08-02T14:56:40.000Z - 4 years ago

Leading Insider Makes Private Investment in TherapeuticsMD Worth $15M

Aug 1, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Jul 13, 2022, 8:25 AM EDT - 4 years ago

TherapeuticsMD's stock falls 41% after tender offer expires

Jul 13, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Expiration of Tender Offer

Jul 6, 2022, 6:09 AM EDT - 4 years ago

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

Jun 6, 2022, 4:05 PM EDT - 4 years ago

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

May 31, 2022, 7:34 PM EDT - 4 years ago

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

May 31, 2022, 1:57 PM EDT - 4 years ago

Here is why TherapeuticsMD jumped 300%

2022-05-31T13:53:53.000Z - 4 years ago

EW Healthcare Partners Acquires TherapeuticsMD; TXMD Shares Surge 350%

May 31, 2022, 6:00 AM EDT - 4 years ago

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 20, 2022, 9:43 AM EDT - 4 years ago

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 16, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD Announces First Quarter 2022 Financial Results

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q1 2022

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Quarterly report: Q1 2022

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Slides: Q1 2022

May 10, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

Apr 14, 2022, 4:15 PM EDT - 4 years ago

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

GDRX

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings release: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Annual report: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Slides: Q4 2021

Mar 10, 2022, 6:50 AM EST - 4 years ago

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Mar 7, 2022, 7:40 AM EST - 4 years ago

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

GDRX

Mar 1, 2022, 4:30 PM EST - 4 years ago

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

Dec 10, 2021, 4:30 PM EST - 4 years ago

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

Dec 8, 2021, 6:50 AM EST - 4 years ago

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Earnings Call Transcript: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Quarterly report: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Earnings release: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Slides: Q3 2021

Nov 11, 2021, 6:50 AM EST - 5 years ago

TherapeuticsMD Announces Third Quarter 2021 Financial Results

Nov 11, 2021, 6:45 AM EST - 5 years ago

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

Oct 27, 2021, 5:00 PM EDT - 5 years ago

TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

Oct 15, 2021, 5:33 PM EDT - 5 years ago

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Sep 21, 2021, 7:45 AM EDT - 5 years ago

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Sep 2, 2021, 6:50 AM EDT - 5 years ago

Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness Month

Aug 23, 2021, 6:50 AM EDT - 5 years ago

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector